title: Rituximab-containing Chemotherapy (R-CHOP)-induced Kaposi's Sarcoma in an HIV-negative Patient with Diffuse Large B Cell Lymphoma.
abstract: Rituximab treatment may cause or exacerbate Kaposi's sarcoma (KS) in patients with human immunodeficiency virus (HIV)-associated multicentric Castleman's disease. Despite the widespread use of rituximab, rituximab-induced KS has not yet been reported in HIV-negative patients with diffuse large B cell lymphoma (DLBCL). We herein report a case of KS that developed after undergoing rituximab-containing chemotherapy in an HIV-negative patient with DLBCL. An 84-year-old man who received rituximab-containing chemotherapy for the treatment of DLBCL developed severe infection, and subsequently KS. Our observations indicate that serious infections under rituximab treatment may trigger KS. KS should therefore be considered when skin tumors appear in lymphoma patients receiving rituximab-containing chemotherapy.
authors.affiliation: Department of Internal Medicine, Karatsu Red Cross Hospital, Japan.
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Ureshino
authors.forename: Toshihiko
authors.initials: T
authors.lastname: Ando
authors.forename: Kensuke
authors.initials: K
authors.lastname: Kojima
authors.forename: Hidekazu
authors.initials: H
authors.lastname: Itamura
authors.forename: Shunichi
authors.initials: S
authors.lastname: Jinnai
authors.forename: Kazuko
authors.initials: K
authors.lastname: Doi
authors.forename: Koichi
authors.initials: K
authors.lastname: Ohshima
authors.forename: Kazuya
authors.initials: K
authors.lastname: Kurogi
authors.forename: Masaharu
authors.initials: M
authors.lastname: Miyahara
authors.forename: Shinya
authors.initials: S
authors.lastname: Kimura
mesh_terms: D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects*; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy*; D008297:Male; D011239:Prednisolone / Q000008:administration & dosage / Q000009:adverse effects; D000069283:Rituximab / Q000008:administration & dosage / Q000009:adverse effects; D012514:Sarcoma, Kaposi / Q000139:chemically induced*; D012878:Skin Neoplasms / Q000139:chemically induced*; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone